AU2022426316A1 - Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound - Google Patents

Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound Download PDF

Info

Publication number
AU2022426316A1
AU2022426316A1 AU2022426316A AU2022426316A AU2022426316A1 AU 2022426316 A1 AU2022426316 A1 AU 2022426316A1 AU 2022426316 A AU2022426316 A AU 2022426316A AU 2022426316 A AU2022426316 A AU 2022426316A AU 2022426316 A1 AU2022426316 A1 AU 2022426316A1
Authority
AU
Australia
Prior art keywords
compound
reaction
added
solvent
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022426316A
Other languages
English (en)
Inventor
Yaya DUAN
Junmin Huang
Shuangjiang Li
Congxin Liang
Guoqiang SHI
Pucha YAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Highlightll Pharmaceutical Co Ltd
Original Assignee
Hangzhou Highlightll Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Highlightll Pharmaceutical Co Ltd filed Critical Hangzhou Highlightll Pharmaceutical Co Ltd
Publication of AU2022426316A1 publication Critical patent/AU2022426316A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AU2022426316A 2021-12-30 2022-12-19 Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound Pending AU2022426316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111658903.5A CN114213424B (zh) 2021-12-30 2021-12-30 一种呋喃[3,2-b]并吡啶衍生物的合成方法
CN202111658903.5 2021-12-30
PCT/CN2022/139966 WO2023125102A1 (zh) 2021-12-30 2022-12-19 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法

Publications (1)

Publication Number Publication Date
AU2022426316A1 true AU2022426316A1 (en) 2024-07-25

Family

ID=80707144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022426316A Pending AU2022426316A1 (en) 2021-12-30 2022-12-19 Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound

Country Status (10)

Country Link
US (1) US20250171458A1 (cg-RX-API-DMAC10.html)
EP (1) EP4509509A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024546195A (cg-RX-API-DMAC10.html)
KR (1) KR20240129021A (cg-RX-API-DMAC10.html)
CN (2) CN114213424B (cg-RX-API-DMAC10.html)
AU (1) AU2022426316A1 (cg-RX-API-DMAC10.html)
CA (1) CA3244846A1 (cg-RX-API-DMAC10.html)
IL (1) IL313966A (cg-RX-API-DMAC10.html)
MX (1) MX2024008276A (cg-RX-API-DMAC10.html)
WO (1) WO2023125102A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201990523A1 (ru) 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3,2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
CN121949334A (zh) * 2024-10-30 2026-05-01 谱尼生物医药科技(上海)有限公司 一种医药中间体7-羟基呋喃并[3,2-b]吡啶的合成方法及其中间体化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
WO2011138657A1 (en) * 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
WO2013051672A1 (ja) * 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN103450125B (zh) * 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
CN105418620B (zh) * 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) * 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
EA201990523A1 (ru) * 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
CN107216334A (zh) * 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
MX2021014319A (es) 2019-06-06 2022-01-26 Highlightll Pharmaceutical Hainan Co Ltd Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo.
EP4393492A3 (en) 2019-06-06 2024-08-07 Hangzhou Highlightll Pharmaceutical Co., Ltd. Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
EP3967694A4 (en) * 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR
WO2021061803A1 (en) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CA3162572A1 (en) * 2019-11-27 2021-06-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tri-heterocyclic compound as jak inhibitor, and use thereof
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3,2-b]并吡啶衍生物的合成方法

Also Published As

Publication number Publication date
EP4509509A4 (en) 2026-06-03
WO2023125102A1 (zh) 2023-07-06
CA3244846A1 (en) 2025-06-13
CN114213424A (zh) 2022-03-22
CN114213424B (zh) 2023-05-26
US20250171458A1 (en) 2025-05-29
JP2024546195A (ja) 2024-12-17
KR20240129021A (ko) 2024-08-27
MX2024008276A (es) 2024-09-02
IL313966A (en) 2024-08-01
EP4509509A1 (en) 2025-02-19
CN118679166A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
EP4509509A1 (en) Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound
Francis et al. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists
CA3039090C (en) Process for preparing btk inhibitors
CA2679754A1 (en) Substituted heterocycle fused gamma-carbolines synthesis
CN115991703A (zh) 并环化合物及其制备方法、药物组合物和应用
AU2023310489A1 (en) Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof
AU2014219754B2 (en) Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method
JP2023089169A (ja) フロイミダゾピリジン化合物の合成方法、フロイミダゾピリジン化合物の結晶形態およびそれらの塩の結晶形態
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用
EP3927689B1 (en) Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
EP3549935A1 (en) Method for producing triazine compound
CN113105436B (zh) 吡唑类化合物的制备方法及其中间体
CN105849115A (zh) 制药方法和中间体
CN116874382B (zh) 一种新斯的明中间体的制备方法
MX2014008814A (es) Proceso para la preparacion de derivados de 2-fenil-[1,2,4]triazol o[1,5-a]piridina.
AU2020397222B2 (en) Process and intermediates for the production of formula (i)
CN119320386A (zh) 一类mettl3抑制剂、其制备方法及其应用
EP4444293A2 (en) Methods of preparing substituted pyrazolopyrimidines
WO2025144783A1 (en) Methods of synthesizing substituted pyrrolopyrimidine compounds
CN115785089A (zh) 一种利奥西呱杂质c的合成方法
CN118900836A (zh) 嘧啶并环类衍生物及其制备方法和用途
WO2019194319A1 (en) Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
CN118271314A (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的制备方法
CN111978321A (zh) 一种4-Boc-2,5,6,7-四氢吡唑并[4,3-b]吡啶及其衍生物的制备方法
HK40016421B (en) Process for preparing btk inhibitors